Fig. 1: Scope and functionality of the KC.

a Precision oncology workflow steps supported by the KC. b Schematic overview of the KC, including (i) meta-information on the tumor sample and the patient and clinical data, (ii) the navigation bar, (iii) content selected via the navigation bar, and (iv) the presentation step consisting of a series of slides and concluding with an editable MTB recommendation and prioritization table and a downloadable report. c Link between molecular and clinical data from individual patients with world knowledge via BoCKs. d Examples of BoCKs. Top, BoCK combining a biomarker (e.g., a specific gene mutation), an entity, a drug or drug class, and published evidence, resulting in a predictive statement with a specific evidence level (EL). Middle, BoCK combining a biomarker, an entity, and published evidence, resulting in oncogenicity classification. Bottom, BoCK combining a biomarker, an entity, and published evidence, identifying eligibility for a specific clinical trial. AC COSMIC (Catalogue Of Somatic Mutations In Cancer) mutational signatures version 2, MSI microsatellite instability, Pub publication, Recom. recommendation, SNV single-nucleotide variant, TMB tumor mutational burden.